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Background: Epithelioid hemangioendothelioma is a malignant, often indolent vascular tumor which occurs at
various anatomic sites. Based on a reciprocal translocation t (1;3)(p36;q25), a consistent WWTR1-CAMTA1 fusion gene
has been found. An alternate YAP1-TFE3 fusion has been detected in a small and distinct subset of cases.
Methods: Thirty-nine tumors, from 24 females and 15 males with an age range 9–85 years, were located in soft
tissue (head and neck [8], trunk [5], upper extremities [3], lower extremities [2], mediastinal [1], and paratesticular
[1]), lymph node (1), breast (1), skin (2), bone (6), lung (7), and liver (2). The cases were investigated using a panel of
immunohistochemical markers. The aforementioned fusion-genes were examined using RT-PCR and/or FISH in
order to validate their diagnostic value.
Results: Follow-up available for 17 patients ranged from 3 months to 7 years (median interval 1.5 years). Eleven
patients were alive without disease, 2 patients were alive with disease after 1.5 and 2 years, respectively. Four
patients died of disease after 4 months (n = 1), 5 months (n = 2), and 1.5 years (n = 1).
The size, known for 30 lesions, was >3 cm in 9 of them. Histologically, all lesions had classical features, at least
focally. Four tumors counted >3 mitoses/50 HPF.
Immunohistochemically, all cases tested stained positive for ERG (21), FLI1 (5) and CD31 (39). CD34 and D2-40
positivity was seen in 81% and 71% of the examined cases, respectively. 11/35 cases expressed pan-keratin and
6/20 cases CK8.18. TFE3 showed a nuclear reaction in 21/24 cases, irrespective of TFE3 rearrangement.
Molecular genetically, 35/35 cases revealed one of the fusion genes by FISH and/or RT-PCR with WWTR1-CAMTA1
in 33 cases and YAP1-TFE3 in 2 cases.
Conclusions: These results demonstrate the high diagnostic value of FISH and RT-PCR in detecting the fusion
genes of EHE. The immunohistochemical utility of TFE3 appears questionable in this study.
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Table 1 Details of used immunohistochemical antibodies
Antibody Clone Dilution Source
ERG EPR3864 1:2000 ABCam, Cambridge, UK
CD31 JC70 A 1:100 DAKO, Glostrup, Denmark
CD34 My10 1:100 BD Biosciences, Heidelberg, Germany
Pankeratin AE1/3 1:50 DAKO, Glostrup, Denmark
CK8.18 CAM5.2 1:10 Becton Dickinson, San Jose, USA
D2-40 D2-40 1:100 DAKO, Glostrup, Denmark
EMA Mc5 1:400 BioGenex, San Ramon, USA
ASMA 1A4 1:500 DAKO, Glostrup, Denmark
S-100 polyclonal 1:2000 DAKO, Glostrup, Denmark
Fli1 polyclonal 1:50 Santa Cruz Biotechnology,
Heidelberg, Germany
TFE3 polyclonal 1:2000 Santa Cruz Biotechnology,
Heidelberg, Germany
INI1 25/BAF47 1:50 BD Biosciences, Heidelberg, Germany
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Epithelioid hemangioendothelioma (EHE), first described
by Weiss and Enzinger in 1982, is a malignant vascular
neoplasm with indolent behavior in the majority of cases
[1]. Although, a progressive clinical course with tumor-
related fatality has been documented in some instances,
this lesion does not behave as aggressively as a conven-
tional angiosarcoma [1-4].
EHEs arise in soft tissue, bone, skin and various paren-
chymatous organs [1-7].
The rarity of this tumor type, combined with the wide
age distribution at presentation, the variety of anatomic
sites and, in some cases, early metastases or multifocal
disease leads to a wide range of differential diagnoses. This
is complicated by the bland epithelioid cytomorphology
and the presence of subtle, mostly intracytoplasmic, vas-
cular lumina [1,2]. Classically, the vacuolated endothelial
cells are arranged in short cords and strands recapitulating
the primitive angiogenic cords of the yolk sac [8].
After discovering the nonrandom reciprocal t
(1;3)(p36;q25) translocation [3], the corresponding
fusion gene WWTR1-CAMTA1 was detected [5,9]. More
recently, an alternative gene fusion, YAP1-TFE3, was found
in a small subset of lesions with distinct morphology and
arising mainly in young patients [10].
In this study we have used a large cohort of cases from
different anatomical sites to investigate the known fusion
genes by fluorescent in situ hybridization (FISH, fusion
probe) and reverse transcriptase-polymerase chain reac-
tion (RT-PCR) in order to validate their diagnostic value.
Furthermore, we have expanded immunohistochemical
data with ERG, the most recently described antibody for
endothelial differentiation, as well as TFE3, one of the
known fusion proteins.
Methods
The cases were retrieved from the (referral) files of the
authors, and clinical details and follow-up were obtained
from the referring physicians. Case 8 was already in-
cluded in the series by Antonescu et al. [10]. The study
was performed in accordance with the Code of Conduct
of the Federation of Medical Scientific Societies in the
Netherlands and Germany.
In all cases, the tissue was fixed in 4% buffered formalin,
routinely processed and embedded in paraffin; 2–4 μm
thick sections were stained with hematoxylin and eosin
and immunohistochemically by the labelled Streptavidin
Biotin technique using commercially available antibodies
listed in Table 1. Appropriate positive and negative con-
trols were used throughout.
Fluorescent in situ hybridization (FISH)
Interphase FISH was performed using a WWTR1-CAMTA1
fusion probe (BACs RP11-1120, RP11-980). The red signal(rhodamine) flanked the distal region of WWTR1 while the
green signal (FITC) labeled the proximal region of the
CAMTA1 gene.
3 μM sections were deparaffinized with xylene and
dried with ethanol after baking at 56°C for 16 hours. All
tissue sections were pre-treated with a 30% solution of
pre-treatment powder in 2xSSC and digested for 10 mi-
nutes with Proteinase K according to the instructions of
the suppliers (MP Biomedicals Illkirch, France). After a
second dehydrating step, the probes were applied to the
sections and the covered slides were sealed with rubber ce-
ment, heat-denatured and hybridized at 37°C for 16 hours.
Subsequently, all sections were counterstained with DAPI I
in mounting medium (1000 ng/ml, Abbott, Wiesbaden,
Germany) and visualized under a Zeiss Axioplan micro-
scope using a HBO103 lamp and the appropriate filters for
the three fluorescent dyes. A negative control was used in
each case. A case was interpreted as positive when at least
10 of 50 counted tumor cells (20%) showed a (yellow)
fusion signal.
Reverse transcriptase-Polymerase chain reaction (RT-PCR)
RNA was extracted from formalin-fixed and paraffin-
embedded tissues (FFPE) using RNA-Bee-RNA isolation
reagent (Bio-Connect BV, Huissen, the Netherlands) ac-
cording to standard procedures. RNA quantity and qual-
ity were determined by NanoDrop measurement (Fisher
Scientific, Landsmeer, the Netherlands) and, subsequently,
cDNA synthesis was performed using Superscript II (Invi-
trogen Life Technologies Europe, Bleiswijk, the Netherlands)
and random hexamers (Promega Nederland, Leiden,
the Netherlands).
The cDNA was tested by the reverse transcription-
polymerase chain reaction (RT-PCR) for the HMBS
(hydroxymethylbilase synthase) housekeeping gene using
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G-3’, rev150 5’-ATGATGGCACTGAACTCCTG-3’, forw250
5’- CTGGTAACGGCAATGCGGCT-3’, rev250 5’- TTCT
TCTCCAGGGCATGTTC-3’.
For detection of the t (1;3) (p26.3;q25) translocation, the
following primers were used: WWTR1 (NM_001168278.1)
forward primers in exon3 5’-GCTGGGAGATGACCTT
CACGGC-3’ and exon4 5’-CCGTCAGTTCCACACCA
GTGCCTC-3’ and CAMTA1 (NM_015215.2) reverse
primers in exon8 rev 5’-GGCTGGGGCTTGGTCTGGT
G-3’ and, because of the use of FFPE tissues with subopti-
mal RNA/cDNA quality, multiple exon9 primers were
used: (1) exon9 rev 5’-GCGAGATGATGCGGTGTTTG
GC-3’, (2) exon 9 rev 5’ CTCGGTGCTGCTCTGGTGCA
G-3’, (3) exon 9 rev 5’- CACCGGGCTGTCCACCATG
TC-3’ and (4) exon 9 rev 5’-GGACAGGCTCTCCGAGC
TGCC-3’.
For the detection of the YAP1-TFE3 fusion, the primers
YAP1 (NM_001130145.2) exon1 forw 5’- CTCCGGAAG
CTGCCCGACTCC-3’ and TFE3 (NM_006521.4) exon4
rev 5’-GAGTGTGGTGGACAGGTACTG-3, TFE3 exon 6
rev 5’- GTTGCTGACAGTGATGGCTGG-3’, TFR3 exon
8 rev 5’-CGGGTCACTGGACTTAGGGATGAGA-3’ and
TFE3 exon 10 rev 5’- CCTGCCCTCCTCCTCAATGT
CC-3’ were used. The PCR products were analyzed by
agarose gel electrophoresis. The sequence of the differ-
ently sized PCR-products was obtained by Sanger se-
quencing and confirmed the presence of the fusion
gene.
Negative controls for RT-PCR were 2 epithelioid hemangi-
omas, 1 epithelioid fibrous histiocytoma, 1 angiosarcoma, 1
epithelioid sarcoma-like/pseudomyogenic hemangioendothe-
lioma and 1 soft tissue angiofibroma.
Results
Clinical data
Clinical data are presented in Table 2.
Of the 39 patients, 24 were females and 15 were males.
The age ranged from 9 to 85 years (mean 50 years; me-
dian 51 years). Anatomical sites of soft tissue lesions
were as follows: head and neck region (8), trunk (5),
upper extremities (3), lower extremities (2), mediastinal
(1) and paratesticular (1). One tumor was located in an
inguinal lymph node, one in the breast, and 2 lesions in
the skin (finger, pubic region). Six neoplasms arose in
the bone and 7 in the lung with multifocal disease in 4
cases. Two tumors were situated in the liver. One of
them showed multifocality. Metastatic disease was diag-
nosed in 11/19 cases with occurrence in lymph nodes
(Cases 2, 24, 28, 35), lung (Cases 19 and 29), pleura (Cases
19, 23, 34, 36), bone (Cases 29 and 34), chest wall (Case
37), mediastinum (Case 19), mesentery (Case 34), and
vulva (Case 32). Three patients had metastases to multiple
sites (Cases 19, 29, 34).All but 3 tumors were treated by surgery with wide exci-
sion in 15 cases and marginal excision in 9 cases. Additional
radiotherapy was applied in 5 cases and metastasectomy
was performed in Cases 2, 24 (cervical lymph node) and 34
(mesentery). One patient (Case 19) received pazopanib
when metastases and progression were obvious. Two
patients were treated by chemotherapy only (Cases 23
and 36). Another patient with multifocal lung disease
received radio-chemotherapy (Case 37).
Follow-up information, available for 17 patients, ranged
from 3 months to 7 years (median interval 1.5 years).
Eleven patients were alive without disease, 2 patients
were alive with disease after 1.5 and 2 years, respectively.
Four patients died of disease after 4 months (n = 1), 5
months (n = 2), and 1.5 years (n=1). Two of them were
children.
The patient from Case 8 had a diagnosis of Langerhans
cell histiocytosis 11 years prior to the EHE. Case 19 was
known with a previously excised cutaneous leiomyosarcoma.
Gross findings
Tumor size ranged from 0.5 to 11 cm (mean 3 cm). The
cut surface appeared solid, white-tan and showed some
hemorrhage in a number of cases.
Histological findings
All tumors showed an infiltrative growth with relatively
sharp demarcation in 13 cases. Multinodularity was ob-
served in 10 cases with separate nodules in some of
these cases. Vasculocentric growth was present in 15 tu-
mors with occasional intravascular expansion and occlu-
sion of larger vessels. Dabska-like intravascular projections
were seen in one case (Case 30). Perineural invasion was
found in 5 tumors (Cases 2, 3, 10, 11, 13).
All lesions were composed of epithelioid cells arranged
in strands, cords and nests. There was also often a his-
tiocytoid cellular appearance. Additional fusiform cells
were seen in 20 cases. Solid highly cellular areas were
encountered in 10 cases (Cases 6, 9, 15, 17, 21, 30, 34,
35, 37, 39) (Figure 1). The nuclei were commonly vesicu-
lar with small often distinct nucleoli. Mild nuclear atypia
was at least focally observed in 16 lesions and striking
nuclear atypia in another 12 cases (Cases 6, 8, 11, 12, 14,
15, 17, 24, 25, 32, 38, 39) (Figures 2 and 3). Mitoses
ranged from 0 to 22/50 HPF. The 2 tumors with the
highest mitotic index showed respectively 12 and 22 mi-
totic figures/50 HPF (Cases 30 and 34). Two lesions
showed 4 mitotic figures/50 HPF (Cases 32 and 37) and
all other lesions did not exceed 3 mitoses/50 HPF. Nu-
clear pseudoinclusions were seen in the cases with in-
creased atypia. All lesions showed an abundant hyaline
cytoplasm with variable intracytoplasmic vacuoles. More
or less well-formed multicellular vascular channels were
present in 11 lesions and this was a prominent feature in
Table 2 Clinical data
Case Sex/Age Site Size (cm) Therapy Rec/Met, m Follow-up
1 f/42y toe 2.0 E NA NA
2 f/63y occipital 1.0 WE, RT, ME cerv LN, 14 NED, 2y
3 f/58y groin NA NA NA NA
4 f/66y lung (mf) NA NA NA NA
5 m/69y oral cavity 0.8 WE - NED, 2y
6 m/42y groin 3.6 NA NA NA
7 m/10y nose bridge 1.1 NA NA NA
8 m/14y LN, groin 2.0 WE NA NA
9 f/70y heel 1.1 NA NA NA
10 m/61y skin/finger 0.5 WE - NED, 2y
11 f/71y neck 1.1 E, R1 - NED, 7y
12 m/51y thoracic spine NA NA NA NA
13 f/30y upper arm 1.9 NA NA NA
14 m/70y lower arm 2.0 NA NA NA
15 f/85y paravertebral 5.4 NA NA NA
16 f/78y breast NA NA NA NA
17 f/41y neck 2.5 WE, RT - NED, 3m
18 f/60y axilla 4.5 E, RT - NED, 1y
19 m/68y lung 1.4 WE, TKI* lung, pleura, mediastinum, 13 AWD, 2y
20 m/54y lung 2.2 WE NA NA
21 m/43y mediastinum 7.5 E NA NA
22 f/46y liver (mf) 4.5 WE - NED, 1y
23 f/70y liver NA CT pleura, 0 AWD, 1.5y
24 m/49y maxilla 3.1 WE, RT,ME cerv LN, 5 NED, 1y
25 f/26y humerus NA E - NED, 5y
26 m/10y paratesticular 1.4 E NA NA
27 f/55y rib 4.5 WE NA NA
28 f/49y mandible 2.5 WE cerv LN NA
29 f/37y neck 3.0 E LN,bone,lung DOD, 4 m
30 f/81y femur NA NA NA NA
31 m/19y lung (mf) NA NA NA NA
32 f/41y groin 1.8 WE, RT Vulva NED, 1y
33 f/77y pubic skin 2.5 WE - NED, 3y
34 m/59y lung 3.0 WE, ME pleura, bone, mesentery, 3 DOD, 1.5y
35 f/25y neck 7.5 E cerv LN, 0 NA
36 f/9y lung (mf) NA CT pleura DOD, 0.5y
37 f/10y lung (mf) 11 CT, RT chest wall DOD, 0.5y
38 m/51y elbow 2.4 E NA NA
39 f/75y neck 2.5 WE NA NA
Rec, Recurrence; Met, Metastases; m, Months; y, Year(s); E, Excision; WE, Wide excision; mf, Multifocal; NED, No evidence of disease; AWD, Alive with disease; DOD,
death of disease; RT, Radiotherapy; CT, Chemotherapy; ME, Metastasectomy; NA, Not available; cerv, Cervical; LN, Lymph node; int jug vein, internal jugular vein;
TKI*, Tyrosine kinase inhibitor pazopanib.
Flucke et al. Diagnostic Pathology 2014, 9:131 Page 4 of 12
http://www.diagnosticpathology.org/content/9/1/131Case 8 (Figure 3). Some lumina were occluded by hya-
line thrombi. A myxohyaline stroma was at least focally
present in all cases and some lesions also induced adesmoplastic reaction. Stroma was absent in highly cel-
lular areas. Fifteen neoplasms had (ischemic) necrosis,
and calcification was seen in 2 lesions (Cases 9 and 10).
Figure 1 Case 6 showed solid areas without a myxohyaline
stroma in addition to the classical morphological features
(lower left).
Figure 3 More vasoformative structures and nuclear atypia was
present in Case 8 which harbored a YAP1-TFE3 fusion.
Flucke et al. Diagnostic Pathology 2014, 9:131 Page 5 of 12
http://www.diagnosticpathology.org/content/9/1/131One tumor contained metaplastic bone (Case 15). Multi-
nucleated giant cells were scattered throughout the lesion
in one case (Case 39). Hemosiderin deposition and a pre-
dominantly marginal inflammatory reaction were seen in
some cases.
According to the criteria by Deyrup et al. [4], 12 tumors
were classified as high risk with a tumor size >3 cm in 9
lesions and a high mitotic rate (>3/50 HPF) in 4 instances
including one tumor which showed both. Of the 6 cases
with follow-up, 2 patients died of disease (Cases 34 and
37; lung lesions) and 4 were alive without evidence of dis-
ease (Cases 18, 22, 24, 32), 2 of them after metastasectomy
(lymph node, vulva). In 8 of the 19 cases fulfilling low risk
criteria, follow-up was available. Six patients (Cases 2, 5,
10, 11, 17, 33) showed no evidence of disease (one after
metastasectomy), while one was alive with metastatic dis-
ease (Case 19) and one died of disease (Case 29).Figure 2 Striking nuclear atypia was seen in approximately
30% of the cases (Case 14).Immunohistochemical findings
The results are shown in Table 3.
21/21 cases were positive for ERG (Figure 4). A mem-
branous reaction for CD31 was demonstrated in all 39
cases (Figure 5) with a focal expression in one case.
CD34 staining was seen in 25/31 (81%) cases with in-
complete reaction in 6 samples. FLI1, performed in 5
cases, showed a positive result in all 5 cases. D2-40 was
positive in 5/7 cases (71%). Two of these cases had a
focal staining pattern. 11/35 lesions (31%) stained posi-
tive for pan-keratin with a focal reaction in 8 tumors.
CK8.18 was focally immunoreactive in 5/20 cases and
strongly reactive in another case (30%). EMA was nega-
tive in 10/11 cases. The positive case showed patchy
staining (9%). ASMA was focally expressed in 1/10 le-
sions (10%). S-100, which was performed in 11 cases,
was patchy positive in 2 of them (18%). INI1 was retained
in all 3 samples tested. TFE3, examined in 24 cases,
showed a nuclear reaction, at least focally, in 21 cases
(88%) (Figure 6), including the two TFE3-rearranged neo-
plasms (Cases 8 and 31).
Molecular genetic findings
Molecular genetic results are presented in Tables 4 and 5.
The analysis failed for both methods in 4 out of 39
cases (Cases 1, 3, 29, 38). The remaining 35 cases re-
vealed one of the known fusion genes with WWTR1-
CAMTA1 positivity in 33 cases (94%) and YAP1-TFE3 in
2 instances (6%).
In the FISH analysis (fusion probe), 23 out of 38 cases
tested, were positive for WWTR1-CAMTA1 (Figure 7)
and 3 were negative (including one with a YAP1-TFE3
fusion). 12 samples showed no hybridization result prob-
ably due to the poor DNA quality.
Using RT-PCR, 25/28 cases were detected to harbor a
fusion gene; 23 were WWTR1-CAMTA1 positive and 2
Table 3 Immunohistochemical analyses
Case ERG CD31 CD34 panCK CK8.18 EMA TFE Others
1 + + f+ + - ND ND D2-40 f+
2 ND + f+ - ND - + S100 -, SMA -
3 ND + - - ND - f+ S100 -
4 ND + - - ND - - S100 -, SMA -
5 ND + ND - ND ND + S100 -
6 ND + + - ND ND f+ SMA -, INI1 +
7 ND + + - ND ND + S100 f+
8 + + ND ND ND ND + SMA -
9 ND + ND ND ND ND f+ SMA -
10 ND + f+ - ND - f+ S100 f+, INI1+
11 ND + + - ND ND f+ Fli1 +, D2-40 -
12 ND + + - ND ND - Fli1 +
13 ND + ND f+ ND ND +
14 ND + + ND ND ND - Fli1 +
15 ND + ND ND ND ND f+ Fli1 +
16 ND + ND - ND ND + D2-40 +
17 + + + f+ - - f+ S100 -, SMA -
18 + + + - - ND +
19 + + + f+ f+ - f+ D2-40 +
20 + + + - - ND f+
21 + + ND - ND ND ND S100 -
22 + + + - f+ ND f+
23 ND + + + + f+ ND D2-40+
24 ND + - f+ f+ - f+ SMA f+
25 ND + + - - ND ND S100 -
26 + + f+ - - ND ND D2-40 -, SMA -
27 + + f+ - - ND ND
28 + + f+ - - ND ND
29 + + - - - - ND S100 -
30 + + - - - - ND SMA -
31 + + + - ND ND f+
32 + + + f+ f+ ND ND S100 -
33 + + + - - ND ND
34 + + + f+ f+ ND ND
35 ND + - f+ ND - ND Fli1+, INI1 +,
36 + + + - - ND ND
37 + + + f+ - ND f+
38 + + ND - ND ND ND SMA -
39 + f+ + + - ND + D2-40 f+
%+ 100 100 81 31 30 9 88
ND, not done; f, focal expression.
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the poor RNA quality. Seven of these cases were positive
for WWTR1-CAMTA1 with FISH. In other words, 8 caseswith a detected fusion gene via RT-PCR showed no signal
with FISH. Additionally, 3 cases which were negative with
RT-PCR had a positive FISH result (WWTR1-CAMTA1).
Figure 4 ERG was positive in all cases tested. Figure 6 TFE3 showed a nuclear reaction in cases with a
WWTR1-CAMTA1 fusion.
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were found: exon 4-exon 8 in 13 cases (Figure 8), exon
4-exon 9 in 7 cases and exon 3-exon 9 in 3 cases.
The fusion-transcript for YAP1-TFE3 were exon 1-exon
4 in both cases (Figure 9).Discussion
Similar to other translocation associated tumors, the t
(1;3)(p36;q23-25) or t(11;X)(q13;p11) translocations are
seemingly early causative events in EHE oncogenesis
[5,11] which initiate a novel transcription program in
cells with endothelial properties [5].
The corresponding fusion proteins, WWTR1-CAMTA1
and YAP1-TFE3, may serve as chimeric transcription fac-
tors, which manifest their oncogenic function via a pro-
moter switch [5,12]. Another possible oncogenic effect
could be due to the loss of regulatory domains of the
C-terminus of WWTR1 or YAP1 and the N-terminus
of CAMTA1 or TFE3 [5].Figure 5 CD31 was strongly expressed in 38/39 cases.WWTR1 on 3q23-24, encodes a transcriptional co-
activator involved in mesenchymal stem cell differenti-
ation and is highly expressed in endothelial cells [5,12],
while CAMTA1, a calmodulin-binding transcription
activator, located on 1p36.23, has been proposed as an
oncogene under the control of the WWTR1 promotor.
The latter is supported by the occurrence of an in-
frame fusion of the C terminus of CAMTA1 to WWTR1,
arguing against loss of function [5].
Alternatively, the YAP1-TFE3 in-frame fusion was re-
cently found in a small and distinct subset of EHE [10].
YAP1, located on 11q13, is a member of the FAT-family
genes similar to WWTR1, and encodes for another WW-
domain containing transcriptional co-activator [10]. The
protein of TFE3, located on Xp11.22, is a member of the
microphtalmia transcription factor family with oncogenic
properties in several tumor types [10,13].
Although these gene fusions have not been identified
in other neoplasms, in particular other epithelioid vascu-
lar tumors, it is not clear yet whether they are unique to
this entity [5,9].
Using both, FISH and RT-PCR, we detected a WWTR1-
CAMTA1 fusion in 23 cases with discrepancies in 5 cases
whereby the results were positive with one method only
(and negative for the other). This could be due to the
primers used missing potentially new breakpoints (RT-
PCR) and possibly a low number of tumor cells show-
ing a fusion signal by FISH.
The known WWTR1 breakpoints are in intron 3 and
4, and the CAMTA1 breakpoints are located in intron 7
and 8, and at different sites within exon 9 [5,9]. The
resulting fusion-transcript variants which we found in
our study were exon 4-exon 8 (n = 13), exon 4-exon 9
(n = 7) and exon 3-exon 9 (n = 3) (listed in decreasing
frequency).
Table 4 Molecular analyses
Case WWTR1-CAMTA1 WWTR1-CAMTA1 YAP1-TFE3
RT-PCR FISH RT-PCR
1 X X X
2 ex4-ex9 X ND
3 X X X
4 ex4-ex8 X ND
5 ex4-ex8 Neg ND
6 X Pos X
7 Neg Pos Neg
8 Neg Neg ex1-ex4
9 ex4-ex8 Pos ND
10 ex4-ex8 Pos Neg
11 ex4-ex9 Pos ND
12 ex4-ex9 X Neg
13 ex4-ex8 Pos ND
14 Neg Pos Neg
15 ex4-ex8 X ND
16 ex4-ex8 X ND
17 ex4-ex8 X ND
18 ex4-ex8 Neg ND
19 ex4-ex9 Pos Neg
20 ex4-ex9 Pos ND
21 Neg Pos Neg
22 ex4-ex9 Pos Neg
23 ex4-ex8 X ND
24 ex4-ex8 Pos ND
25 ex3-ex9 Pos Neg
26 X Pos X
27 ex4-ex8 Pos ND
28 X Pos X
29 X X X
30 ex4-ex8 Pos ND
31 Neg ND ex1-ex4
32 X Pos X
33 X Pos X
34 ex3-ex9 Pos Neg
35 ex4-ex9 Pos ND
36 ex3-ex9 X Neg
37 X Pos X
38 X X X
39 X Pos X
23 cases Pos 23 cases Pos 2 cases Pos
Ex, exon; neg, negative; pos, positive; x, failed; ND, not done.
Table 5 Fusion-transcripts for both fusion genes
WWTR1-CAMTA1 Number of cases
exon 4-exon 8 13
exon 4-exon 9 7
exon 3-exon 9 3
YAP1-TFE3 Number of cases
exon 1-exon 4 2
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YAP1-TFE3 by RT-PCR. One of them (Case 8) was in-
cluded in the study by Antonescu et al. [10], in which
the gene fusion was demonstrated by FISH. This case
was not only remarkable because of the histomorpholo-
gical characteristics as reported in the mentioned paper
[10] but also because it occured in a lymph node as the
primary site. A more frequently occurring metastasis
should be excluded in such cases [2,14]. In contrast, the
other case with a YAP1-TFE3 fusion showed a classical
morphology of a multifocal lung EHE (Case 31). Inter-
estingly, these 2 cases involved adolescents/young adults
in concert with the finding of young age reported by
Antonescu et al. [10].
TFE3 rearrangements are also present in alveolar soft
part sarcoma, certain pediatric renal cancers and a sub-
set of PEComas [15-18]. The use of an antibody against
the C-terminal portion of TFE3 seems to be a useful
diagnostic tool in all rearranged tumors [10,19], but one
has to be aware of an unspecific staining pattern [17] as we
found in a proportion of cases with WWTR1-CAMTA1
fusion.
ERG and FLI1 are transcription factors of the ETS-
family which are expressed in endothelial cells. In addition
to CD31, these 2 markers are helpful in highlighting theFigure 7 FISH identified a fusion of WWTR1-CAMTA1.
Figure 8 Sequencing of the RT-PCR product shows an in-frame
fusion between exon 4 of WWTR1 and exon 8 of CAMTA1 in the
chimeric transcript in 13 cases.
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in all cases examined. These markers are of course
expressed in all other vascular lesions [8,20,21], there-
fore, detection of the aforementioned fusion genes may
be a valuable discriminatory tool in diagnosing EHE,
especially in difficult cases.
In 2008, a proposal for risk stratification was made
based on clinicopathological features of 49 soft tissue
EHEs. It seems that higher mitotic activity (>3/50 HPF)
and tumor size exceeding 3 cm are associated with
higher mortality, irrespective of anatomic site, presence
of cytological atypia, tumor cell spindling, or necrosis
[4]. Due to the small number of our cases with available
clinical data, we were able to show only tendencies for
the low-risk and high-risk category. Furthermore, in skin
lesions, a favorable outcome is well known similar to
all other sarcomas at this site [2]. Whether it is useful
to include lung-, liver- and bone lesions in this risk
stratification scheme remains uncertain so far, espe-
cially with respect to multifocal occurrence (or early
metastases) [9].
Differential diagnoses of EHE depend on anatomic site
and age. Carcinomas, myoepithelial tumors, epithelioidFigure 9 YAP1 exon1 was fused to TFE3 exon 4 in two cases
(ABI sequence).sarcoma, mesothelioma, extraskeletal myxoid chondro-
sarcoma, myxoid liposarcoma and especially other vascu-
lar tumors with epithelioid morphology, such as epithelioid
hemangioma, cutaneous epithelioid angiomatous nodule,
epithelioid angiosarcoma and pseudomyogenic heman-
gioendothelioma (epithelioid sarcoma-like hemangioen-
dothelioma, PM-H) can enter the differential diagnoses
[1,2,8,22-24]. In bone, chondrosarcoma can also be a po-
tential pitfall.
Epithelioid hemangioma occurring in skin, soft tissue
and bone is distinguished by a lobular architecture of
well-formed vessels with a pericytic cuff, highlighted by
ASMA/MSA (muscle specific actin) immunohistochemi-
cal reaction [1,22,25,26]. In the center of the lesion, the
plump epithelioid cells are sometimes rather tightly
packed and arranged in solid sheets simulating a more
aggressive tumor. The distinctive zonation pattern with
peripheral maturation is a helpful finding [25,26]. A myxo-
hyaline stroma is not a feature of epithelioid hemangioma.
As in EHE, vascular invasion can occur. Multifocality of
epithelioid hemangioma with involvement of soft tissue
and/or bone, skin and lymph nodes should not be con-
fused with metastases of EHE [26,27].
Cutaneous epithelioid angiomatous nodule is a circum-
scribed lesion composed of a sheet-like proliferation of epi-
thelioid cells with eosinophilic cytoplasm. Intracytoplasmic
vacuoles are numerous and mitotic figures can be present.
This lesion lacks cords and strands of tumor cells in a
myxohyaline or fibrous stroma which is seen in EHE [22].
Epithelioid cells with eosinophilic cytoplasm are present
to a variable extent in approximately 70% of angiosarco-
mas (AS) of soft tissue [23] and, of course, they can be
prominent in AS at other sites as bone, skin and paren-
chymatous organs. There is considerable nuclear pleo-
morphism present and a high mitotic index, which are not
typical features of EHE. Lumen formation ranges from ir-
regular vascular channels to intracytoplasmic vacuoles or
when absent there can be a diffuse, nest- or sheet-like
growth pattern. The hemorrhagic background seen in
angiosarcoma is not characteristic for EHE. Keratins can
be expressed in both EHE and angiosarcomas (in ca. 30%
of the cases, respectively) [23].
Pseudomyogenic hemangioendothelioma (epithelioid
sarcoma-like hemangioendothelioma, PM-H) is com-
posed of loose fascicles and sheets of plump spindle
cells and/or epithelioid cells with vesicular nuclei and
bright eosinophilic cytoplasm. A myxoid background
rarely exists in PM-H and (intracytoplasmic) vascular
formations are described as more elusive. Angiocentric
growth may occur in both entities. Expression of kera-
tins is an overlapping feature, although CD34 and pan-
keratin MNF116 are lacking in PM-H [8,24]. Recently,
SERPINE1-FOSB, has been identified as a specific fu-
sion gene in PM-H [28].
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mitotically active tumors [1] evoking a desmoplastic re-
sponse and usually exhibit stronger keratin expression
whereas endothelial markers are absent.
Myoepithelial tumors are composed of variable pro-
portions of epithelioid, spindle, clear and/or plasmocy-
toid cells. However, cords and strands embedded in a
(chondro) myxoid/hyaline matrix is a shared feature and
cytoplasmic vacuolation can occur [29]. Endothelial markers
are absent in myoepithelial tumors. S-100 and keratins, usu-
ally expressed in myoepithelial tumors [29], can also be oc-
casionally positive in EHE as demonstrated in two of our
cases [2]. EWSR1 and PLAG rearrangements are character-
istic genetic changes in myoepithelial tumors [30-33].
Extraskeletal myxoid chondrosarcoma shows a multi-
nodular architecture. The monomorphous small round
or short spindle cells are loosely arranged and show deli-
cate anastomosing strands distributed in a prominent
myxoid stroma. Although some vacuolated cells can be
observed, the cytoplasm is more eosinophilic [1,34] and
vascular markers are not expressed. NR4A3 rearrange-
ment is a pathognomonic genetic aberration [35].
Conventional epithelioid sarcoma (ES) tends to grow
in confluent nodules with central necrosis or hyaliniza-
tion. The epithelioid to spindled cells show deeply eo-
sinophilic cytoplasm. Vacuolated cells can possibly be
confused with intracytoplasmic lumina of EHE [36]. When
the matrix is myxoid, there are often still prominent colla-
gen bundles [37], a feature which is not seen in the myxo-
hyaline stroma of EHE. Immunohistochemically, this
tumor type typically shows keratin- and EMA-expression,
loss of INI1 [38] and occasionally a membranous CD31
staining [39]. CD34 and D2-40 can be either positive or
negative in both tumor types [40-42]. Interestingly, ERG
and FLI1 (antibody to the N-terminus) expression was
recently shown in up to 70% and more than 90% of ES,
respectively [40,41]. Therefore, these markers can only
be interpreted in the right context together with CD31
and INI1. The latter is retained in EHE [38] as shown
in some of our cases.
Myxoid liposarcoma shows a prominent myxoid matrix
with enhanced cellularity at the periphery of the tumor nod-
ules. The primitive cells are uniformly round to oval-shaped.
Small signet ring lipoblasts could possibly be confused with
the vacuolated cells of EHE, but there is no abundant pale-
eosinophilic cytoplasm in a myxoid liposarcoma. The deli-
cate arborizing vasculature in myxoid liposarcoma is very
characteristic. When genetics are taken into account, DDIT3
is the consistent fusion partner in this lesion [42].
As well as the aforementioned vascular lesions, chondro-
sarcoma is an important differential diagnosis in primary
bone tumors and shows uniform atypical chondroblasts
suspended in an extensive myxoid matrix. Cytoplasmic
vacuolation can be misinterpreted but the nuclei inchondrosarcoma are hyperchromatic and the scant cyto-
plasm is eosinophilic [42]. Vascular immunohistochemical
markers are absent.
Epithelioid mesothelioma could be a relevant differen-
tial diagnosis at appropriate sites because of the abun-
dant, sometimes vacuolated cytoplasm of mesothelial
cells and the possible myxoid stroma. Although pankera-
tin and D2-40 can be positive in both malignancies, as
also demonstrated in a number of our cases, calretinin,
keratin 5/6, keratin 7, and WT1 are typically distinguish-
ing mesotheliomas [43].
Conclusions
The identification of the fusion genes in EHEs provides
important diagnostic information, especially in cases with
aberrant morphology or when biopsy material is limited.
Moreover, clinicopathologic and research studies can be
objectified based on these molecular fusion events, and
biological and prognostic information will possibly influ-
ence therapeutic approaches.
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